The website of the Clinical Services Journal

Over 600 people set to benefit from innovative lung cancer treatment

​More than 600 people could benefit from an innovative drug for a form of lung cancer as NICE publishes final draft guidance recommending osimertinib within the Cancer Drugs Fund (CDF).

Osimertinib (also known as Tagrisso and made by AstraZeneca) is recommended for people with early-stage (1b to 3a) non-small-cell lung cancer (NSCLC) who have had surgery to remove their tumour and who have epidermal growth factor receptor (EGFR) gene mutations.

Current clinical trial evidence shows that compared with active monitoring, adjuvant treatment with osimertinib reduces the risk of the disease coming back by 80%. It may also lower the risk of dying from their cancer. However, this evidence is uncertain because information from the trial was released early, and the data is still immature. For this reason the drug is recommended for use within the CDF rather than in routine NHS commissioning.

The CDF recommendation means people with this form of lung cancer will be able to have osimertinib on the NHS while further evidence is gathered on its clinical and cost-effectiveness.

Professor Gillian Leng, Chief Executive at NICE said: “I am delighted we are able to recommend osimertinib within the Cancer Drugs Fund for people with this type of lung cancer. Osimertinib shows real potential in being able to stop people’s cancer from reccurring following surgery.

“For people at this stage of their cancer treatment and with this type of lung cancer, treatment options are extremely limited. Osimertinib is a promising treatment in a new place in the treatment pathway and today’s decision will be welcome news for them and their families.”

EGFR mutations occur in approximately 10% of people with lung cancer in the UK. It is a protein that helps cells in the body to grow. A mutation in the gene for EGFR can make this protein grow too much, which can cause cancer.

According to the company there are around 600 people in England who would be eligible for the treatment. Osimertinib works by blocking EGFR and may help to slow or stop the lung cancer from growing. It may also help to reduce the size of the tumour and prevent the tumour from coming back after removal by surgery.

Upcoming Events

AfPP Annual Conference 2022

University of York
8-11 September 2022

Infection 360: What's trending in infection prevention & control

Edgbaston Stadium, Birmingham
27-28 September 2022

IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022

Bournemouth
17-19 October 2022

UKHCA Conference: Listen Up

Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022

MEDICA 2022

Dusseldorf Germany
14th November - 17th November

Future Surgery 2022

ExCel, London
15th - 16th November 2022

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Upcoming Events

AfPP Annual Conference 2022

University of York
8-11 September 2022

Infection 360: What's trending in infection prevention & control

Edgbaston Stadium, Birmingham
27-28 September 2022

IP2022 IS COMING TO BOURNEMOUTH IN OCTOBER 2022

Bournemouth
17-19 October 2022

UKHCA Conference: Listen Up

Pendulum Hotel and Manchester Conference Centre, Manchester
3rd November 2022

MEDICA 2022

Dusseldorf Germany
14th November - 17th November

Future Surgery 2022

ExCel, London
15th - 16th November 2022

Access the latest issue of Clinical Services Journal on your mobile device together with an archive of back issues.

Download the FREE Clinical Services Journal app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2022 Step Communications Ltd. Registered in England. Registration Number 3893025